RNA in Non-Small-Cell Lung Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 921
Special Issue Editor
Special Issue Information
Dear Colleagues,
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer death worldwide. Patients often face resistance to common therapies, showing a poor prognosis. In fact, despite recent advances, most patients are diagnosed at advanced stages, with a very low overall survival. Therefore, the identification of new effective diagnostic and therapeutic strategies for NSCLC patients is a crucial challenge in oncology.
In this context, non-coding RNAs (ncRNAs), key regulators of gene expression at transcriptional and post-transcriptional levels, represent a promising class of molecules. Through cancer cell profiling, miRNAs and lnc-RNAs, which importantly contribute to NSCLC molecular characterization, can be identified and used for effective diagnosis. Moreover, based on their role, miRNAs and lnc-RNAs can also enable the design of innovative NSCLC therapeutics. In addition to endogenous ncRNAs, such as miRNAs and lnc-RNAs, exogenous ncRNAs, including Antisense Oligonucleotides (ASOs), short interfering RNAs (siRNAs) and RNA aptamers, are very promising for NSCLC diagnosis and/or target therapy.
This Special Issue will report recent advancements in the field of ncRNAs in NSCLC, covering key aspects of their applications in diagnosis and target therapy.
Dr. Silvia Catuogno
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- NSCLC
- non-coding RNAs
- miRNAs
- lnc-RNAs
- ASOs
- siRNAs
- aptamers
- diagnosis
- target therapy
